Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.73 |
| ▸ | DRD4 | P21917 | 3/20 | 0.73 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.73 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | HTR1B | P28222 | 1/20 | 0.73 |
| ▸ | HTR7 | P34969 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051902 | 1.00 | HTR1A (0.73) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL8011497 | 1.00 | HTR1A (0.73) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL14275261 | 0.86 | HTR1A (0.83) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL8410968 | 0.86 | OPRM1 (0.68) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL8544239 | 0.86 | OPRM1 (0.68) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| Way-100,635 SCHEMBL29451114 | 0.85 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| Way-100,635 SCHEMBL84178 | 0.85 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| Way-100,635 SCHEMBL30720034 | 0.85 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| Way-100,635 SCHEMBL13398069 | 0.85 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| Way-100,635 SCHEMBL29486911 | 0.84 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6127357-A | N-((phenyl, benzodioxinyl or N-heteroarylpiperazinyl)alkyl)-N-(N-heteroaryl)substituted carboxamides | JOHN WYETH & BROTHER, LTD. (GB) | 2000-10-03 | — | — | US | claimed |
| EP-0512755-B1 | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| EP-0512755-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1992-11-11 | — | — | EP | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-6127357-A | N-((phenyl, benzodioxinyl or N-heteroarylpiperazinyl)alkyl)-N-(N-heteroaryl)substituted carboxamides | JOHN WYETH & BROTHER, LTD. (GB) | 2000-10-03 | — | — | US | disclosed |
| EP-0763024-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033725-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1995-12-14 | — | — | WO | disclosed |
| EP-0512755-B1 | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1994-12-14 | — | — | EP | disclosed |
| EP-0512755-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885ADRA1A 514/4885DRD4 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.